Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice
Targeting FOLR1 with an approved antibody-drug conjugate restored anti-tumor immunity and enhanced anti-PD-1 effectiveness in colorectal cancer, overcoming immune evasion in mouse models. The post Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice appeared first on GEN - Genetic Engineering and Biotechnology News .
Colorectal cancer (CRC) ranks third globally among cancer cases. Despite immune checkpoint blockade showing promise, only 15% of patients experience significant benefits from treatments such as anti-PD-1. A new study reveals that folate receptor sustains colorectal cancer's ability to resist immunotherapy. Targeting this receptor with a drug could restore the treatment's efficacy in mice, suggesting that integrating folate receptor-based treatments into existing regimens could improve outcomes for patients with treatment-resistant tumors.
Published in Science Translational Medicine, the study titled "Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti-PD-1 efficacy in colorectal cancer" finds that high expression of the folate receptor α (FOLR1) predicts poor immune checkpoint blockade (ICB) response, increased cancer stemness, and unfavorable patient outcomes.
The research demonstrates that mirvetuximab soravtansine, an approved antibody-drug conjugate that inhibits FOLR1, restores anti-tumor immunity and re-sensitizes colorectal cancer tumors to anti-PD-1 blockade in mice.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.